Clinical trials: Clozapine Resistant Schizophrenia
Schizophrenia
A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia
Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long term treatment of clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT00154258
- Testing
- Clozapine
- Volunteers
- 19 people
- Sponsor
- Novartis
Schizophrenia
Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study
The purpose of this study is to investigate the relationship between glutamate and related brain chemicals and treatment response to clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT02714894
- Testing
- Clozapine
- Where
- Canada
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Treatment-resistant Schizophrenia
Neural Biomarkers of Clozapine Response
Clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown.
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT03076346
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pittsburgh
Schizophrenia
Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment
We propose an eight-week, double-blind, placebo-controlled trial of rosiglitazone in schizophrenia subjects treated with clozapine using Bergman's Minimal Model (MINMOD) intravenous glucose tolerance test.
- Trial name
- NCT00337350
- Testing
- rosiglitazone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Metabolic Syndrome
Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia
We are going to investigate the association of multiple genetic polymorphisms with the metabolic side effects in patients with schizophrenia taking clozapine.
- Conditions
- Schizophrenia, Metabolic Syndrome, Genetic Polymorphism
- Trial name
- NCT00717509
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National Hospital
Sialorrhea
Clozapine-induced Hypersalivation - Feasibility Trial
A randomised placebo-controlled feasibility study of glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation to assess recruitment and retention rates in a multi-centre trial.
- Trial name
- GOTHIC1 (NCT02613494)
- Testing
- Hyoscine, Glycopyrrolate
- Where
- 2 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Mersey Care NHS Trust
Schizophrenia, Schizoaffective Disorder
Polypharmacy in Clozapine-resistant Schizophrenia
The aim of this randomized, double-blind study is to verify the hypothesis that clozapine monotherapy is as efficient as a combination of clozapine and olanzapine therapy in treatment-resistant schizophrenia.
- Trial name
- CLOZANS (NCT00918021)
- Testing
- olanzapine
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Niuvanniemi Hospital
Schizophrenia
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia. This study is not recruiting in the United States.
- Trial name
- NCT00250575
- Testing
- Clozapine
- Where
- 8 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Novartis
Schizophrenia
Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
This study will determine the effectiveness of clozapine versus olanzapine in treating people with schizophrenia that has not improved with treatment.
- Trial name
- COES (NCT00169065)
- Testing
- Clozapine, Olanzapine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Harvard Medical School (HMS and HSDM)
Schizophrenia
Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
This study is a six-week, open label trial of the novel antipsychotic agent, ziprasidone, added to a stable dose of clozapine or olanzapine in 40 diabetes mellitus patients, patients with an impaired fasting glucose or insulin…
- Trial name
- NCT00351000
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Psychosis, Intellectual Disability
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
This clinical trial will prove whether a large number of people with intellectual disability and treatment-resistant psychosis could benefit from the use of clozapine.
- Trial name
- CLOZ-AID (NCT04529226)
- Testing
- Clozapine, haloperidol, pimozide, olanzapine, risperidone, amisulpride
- Where
- 20 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Schizophrenia
Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine
Clozapine has been virtually the only psychopharmacological choice in patients with schizophrenia who either did not response to typical neuroleptics or experienced severe extrapyramidal side effects and consequently did not…
- Trial name
- NCT01401491
- Testing
- clozapine plus fluvoxamine
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University Hospital
Metabolic Syndrome
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes.
- Trial name
- ATOMICS (NCT00794963)
- Testing
- Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Treatment Resistant Schizophrenia, Clozapine Adverse Reaction
Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial.
Clozapine is the only drug approved for Treatment Resistant Schizophrenia. However, it has been associated with many adverse drug reactions including agranulocytosis, myocarditis, sialorrhea, constipation, orthostasis…
- Conditions
- Treatment Resistant Schizophrenia, Clozapine Adverse Reaction, Heart Rate Variability, Tachycardia
- Trial name
- NCT06505668
- Testing
- Atenolol 25 mg, Ivabradine 10mg
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia
A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia
This pilot study is an eight-week, randomized, double-blind, placebo-controlled, escalating dose trial of the novel vigilance-promoting drug, modafinil, added to a stable dose of clozapine in 40 patients with schizophrenia or…
- Trial name
- NCT00573417
- Testing
- modafinil
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia
Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)
Clozapine treatment resistant schizophrenia is still prevalent.The effectiveness of augmenting clozapine : one augmenting with haloperidol and the other with electroconvulsive therapy should be determined.This study is a…
- Trial name
- TCRS (NCT00753051)
- Testing
- clozapine+haloperidol, clozapine,electroconvulsive therapy
- Where
- Thailand
- Volunteers
- 18 people
- Sponsor
- Khon Kaen University
Weight Gain, Sialorrhea
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or…
- Trial name
- FOCUS (NCT00683891)
- Testing
- FazaClo (clozapine, USP) ODT
- Where
- 2 sites in United States
- Sponsor
- Azur Pharma, Inc
Treatment-resistant Schizophrenia
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine
The specific aim of this protocol is to compare Clozapine treatment vs Non-Clozapine antipsychotic treatment in a population of treatment-refractory individuals with schizophrenia.
- Trial name
- NCT05741502
- Testing
- Clozapine, Antipsychotics,Other (non-Clozapine)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ohio State University
Schizophrenia, Insulin Resistance
Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
This study will evaluate the effects of combination treatment with aripiprazole and clozapine on insulin resistance, blood fat levels, and weight gain in people diagnosed with schizophrenia.
- Trial name
- NCT00345033
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation to Clozapine
The proposed pilot study will compare minocycline augmentation with clozapine in individuals with high vs low inflammation as measured by CRP.
- Trial name
- NCT02124811
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University